NEWS
UK’s first norovirus mRNA vaccine trial launched
The first Phase 3 randomised clinical trial of an investigational mRNA norovirus vaccine will open across the UK within the next few weeks. Sponsored by Moderna, the trial evaluates the efficacy and safety of a norovirus vaccine called mRNA-1403. There are currently no licensed norovirus vaccines in use anywhere in the world. The trial will take place at 39 sites across the country. This includes 27 NHS primary and secondary care sites. It aims to recruit 2,500 participants in the UK over the next few months.
The UK Chief Investigator is Dr Patrick
Moore, a Dorset GP and Research Director at the NIHR’s South West Regional Research Delivery Network. The trial is being run in the UK as part of a unique 10-year partnership between Moderna and the UK Health Security Agency (UKHSA) on behalf of the UK Government, the Moderna-UK Strategic Partnership. Set up and delivery of the trial is being supported by the UK Vaccine Innovation Pathway (VIP) and
®
the NIHR. They are working together to accelerate vaccine trials in the UK. The NIHR Research Delivery Network (RDN) is working with the devolved administrations to speed up the roll-out of key vaccine studies. They do this through accelerated contracting and set-up. The trial is making use of different recruitment strategies. Researchers are seeking participants 60 years of age and older, as this age group is generally more likely to be severely affected by norovirus. Any future vaccine would benefit them most.
IBMS report: modernisation needed in UK diagnostic services
A new report from the Institute of Biomedical Science (IBMS), in partnership with PA Consulting, provides a strategic roadmap for modernising diagnostic services in the UK, while highlighting the need for technological advancements. The report Earlier Diagnostics: Innovation, is the first in a three-part series that outlines a stepwise approach essential for future-proofing diagnostic services, against a background of rising diagnostic demands, workforce shortages, and increasing healthcare complexities. Drawing from insights developed at
a roundtable that convened healthcare, industry, and commissioning body leaders from across the UK, the report presents a 1-2-3 approach for implementing appropriate diagnostic technology. It begins with standardisation to establish consistent processes and workflow, followed by connecting IT systems for speed of communication and collaboration, and then unlocking the full potential of AI and advanced technologies to transform diagnostic accuracy and speed.
IBMS Chief Executive David Wells commented: “As diagnostic demands grow, this strategic approach offers the guidance needed to make transformative advances in patient care while supporting the diagnostic workforce. Each stage, from standardisation to AI adoption, creates a more resilient, accessible, and sustainable diagnostic service.” The report focuses on three key steps:
n Standardisation as the foundation: Implementing uniform diagnostic standards across healthcare networks to support the integration of new technologies and improve consistency in patient care.
n Connected IT systems: Developing IT platforms that link laboratories, clinicians, and patients in real-time, allowing for more efficient data sharing and faster diagnostic results.
n Adoption of AI and automation: Leveraging AI-driven tools, digital pathology, and laboratory automation to enhance diagnostic accuracy, reduce turnaround times, and relieve workforce strain.
WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2024
Highly sensitive and specific carbapenemase detection
IVD solutions through partnership
MAST CARBA PAcE
Rapid Simple Cost effective
MAST CARBA PAc ®
Contact us on
sales@mast-group.com
9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
